Emactuzumab RG 7155; RO 5509554|cas:1448221-67-7|西域试剂

Emactuzumab RG 7155; RO 5509554,97.60%

产品编号：Bellancom-P99245| CAS NO：1448221-67-7

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P99245	￥4100.00	杭州北京（现货）
Bellancom-P99245	￥9000.00	杭州北京（现货）
Bellancom-P99245	￥14000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Emactuzumab RG 7155; RO 5509554

产品介绍

Emactuzumab (RG 7155) 是一种特异性单克隆抗体，可抑制集落刺激因子 1 受体 (CSF1R) 的激活。Emactuzumab 对 CSF-1R 具有高亲和力，K_i 值为 0.2 nM，可阻断 CSF-1R 二聚化。Emactuzumab 可用于多种疾病的研究，如弥漫型腱鞘巨细胞瘤（dt-GCT）。

生物活性

Emactuzumab(RG 7155) is a specific monoclonal antibody that inhibits colonystimulating factor 1 receptor (CSF1R) activation. Emactuzumab has high affinity for CSF-1R with K_i value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab can be used for the research of several diseases, such as diffuse-type tenosynovial giant cell tumour (dt-GCT) .

体外研究

Emactuzumab (RG 7155) binds to human and cynomolgus CSF-1R with high affinity (K_d = 0.2 nM) to blocks CSF-1R dimerization.
RG7155 (0-10 μg/mL, 7 days) potently inhibited the viability of CSF-1-differentiated macrophages with an IC₅₀ of 0.3 nM by inducing cell death.
RG7155 (30 μg/mL, 6 days) induces cell death of in vitro-differentiated human M2-like macrophages.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	CSF-1 and/or GM-CSF Macrophages
Concentration:	0-10 μg/mL
Incubation Time:	7 days
Result:	Resulted cell death of CSF-1-differentiated macrophages.

体内研究
(In Vivo)

Emactuzumab(RG 7155) (i.v.; 0.1、1、10、30 and 100 mg/kg; once) increases CSF-1 concentration in nonhuman primates’ peripheral blood.
RG7155 (i.v.; 0, 30, and 100 mg/kg; once weekly; for 2 weeks) depletes CSF-1R⁺CD163⁺ macrophages in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	cynomolgus monkeys Macaca fascicularis
Dosage:	0.1, 1, 10, 30 and 100 mg/kg (male cynomolgus monkeys) 0, 30, and 100 mg/kg (male and female cynomolgus)
Administration:	i.v., once (male cynomolgus monkeys) i.v., once weekly, for 2 weeks(male and female cynomolgus)
Result:	Increased CSF-1 concentration in serum. Efficiently reduced CSF-1R and CD68⁺163⁺ macrophages in the liver (Kupffer cells) and colon of cynomologus monkeys.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	cynomolgus monkeys Macaca fascicularis
Dosage:	0.1, 1, 10, 30 and 100 mg/kg (male cynomolgus monkeys) 0, 30, and 100 mg/kg (male and female cynomolgus)
Administration:	i.v., once (male cynomolgus monkeys) i.v., once weekly, for 2 weeks(male and female cynomolgus)
Result:	Increased CSF-1 concentration in serum. Efficiently reduced CSF-1R and CD68⁺163⁺ macrophages in the liver (Kupffer cells) and colon of cynomologus monkeys.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	cynomolgus monkeys Macaca fascicularis
Dosage:	0.1, 1, 10, 30 and 100 mg/kg (male cynomolgus monkeys) 0, 30, and 100 mg/kg (male and female cynomolgus)
Administration:	i.v., once (male cynomolgus monkeys) i.v., once weekly, for 2 weeks(male and female cynomolgus)
Result:	Increased CSF-1 concentration in serum. Efficiently reduced CSF-1R and CD68⁺163⁺ macrophages in the liver (Kupffer cells) and colon of cynomologus monkeys.